Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) was the recipient of a significant decline in short interest in June. As of June 30th, there was short interest totalling 74,200 shares, a decline of 20.0% from the May 30th total of 92,700 shares. Approximately 2.3% of the company’s shares are sold short. Based on an average daily trading volume, of 346,100 shares, the short-interest ratio is presently 0.2 days.
DFFN has been the topic of a number of recent research reports. ValuEngine cut shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. HC Wainwright reaffirmed a “buy” rating on shares of Advanced Emissions Solutions in a research report on Wednesday, March 20th.
DFFN stock remained flat at $$2.18 during midday trading on Friday. 230,606 shares of the company’s stock were exchanged, compared to its average volume of 116,902. The stock has a market capitalization of $7.37 million, a P/E ratio of -0.36 and a beta of -0.02. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.35 and a current ratio of 5.35. Diffusion Pharmaceuticals has a 1 year low of $1.83 and a 1 year high of $11.00. The stock has a fifty day simple moving average of $2.97.
An institutional investor recently bought a new position in Diffusion Pharmaceuticals stock. Two Sigma Investments LP bought a new position in shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 32,176 shares of the company’s stock, valued at approximately $64,000. Two Sigma Investments LP owned approximately 0.95% of Diffusion Pharmaceuticals at the end of the most recent quarter. Institutional investors own 6.20% of the company’s stock.
Diffusion Pharmaceuticals Company Profile
Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke.
Featured Article: Cost of Goods Sold (COGS)
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.